SCHEMBL166799

SCHEMBL166799

CCOC(=O)CCC(F)(F)COS(=O)(=O)C(F)(F)F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.36
GAA P10253 2/20 0.34
MGAM O43451 1/20 0.34
SI P14410 1/20 0.34
MGAM2 Q2M2H8 1/20 0.34
SMN1; SMN2 Q16637 5/20 0.34
HPGD P15428 3/20 0.34
MAPK1 P28482 3/20 0.34
TP53 P04637 2/20 0.34
KMT2A Q03164 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
HSD17B10 Q99714 2/20 0.34
TLR9 Q9NR96 2/20 0.34
S1PR4 O95977 1/20 0.34
LMNA P02545 1/20 0.34
S1PR1 P21453 1/20 0.34
STAT3 P40763 1/20 0.34
STAT1 P42224 1/20 0.34
ALDH1A1 P00352 3/20 0.32
TRPA1 O75762 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15052067 0.84 CYP1A2 (0.35) CYP1A2GAAMGAMSIMGAM2
SCHEMBL25339223 0.81
SCHEMBL32679464 0.80 APEX1 (0.32)
SCHEMBL1700886 0.79 CYP1A2 (0.48) CYP1A2GAAMGAMSIMGAM2
SCHEMBL1730503 0.76 GAA (0.41) CYP1A2GAAMGAMSIMGAM2
SCHEMBL21853321 0.76 CYP1A2 (0.42) CYP1A2GAAMGAMSIMGAM2
SCHEMBL15071341 0.76 CYP1A2 (0.45) CYP1A2GAAMGAMSIMGAM2
SCHEMBL4880094 0.75 DGKA (0.43) CYP1A2GAAKMT2AHSD17B10ALDH1A1
SCHEMBL166315 0.74 CYP1A2 (0.44) CYP1A2GAAMGAMSIMGAM2
SCHEMBL8421725 0.74 SMN1; SMN2 (0.36) CYP1A2GAAMGAMSIMGAM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121574090-A Gelagliptin intermediate Process for the preparation of bulk compounds 四川定科制药有限公司 2026-02-27 CN disclosed
EP-2611776-B1 PRODUCTION METHOD OF INTERMEDIATE COMPOUND FOR SYNTHESIZING MEDICAMENT LG LIFE SCIENCES LTD (KR) 2016-09-21 EP disclosed
US-8741927-B2 Production method of intermediate compound for synthesizing medicament LG LIFE SCIENCES LTD. (KR) 2014-06-03 US disclosed
US-8741927-B2 Production method of intermediate compound for synthesizing medicament LG LIFE SCIENCES LTD. (KR) 2014-06-03 US disclosed
EP-2611776-A2 PRODUCTION METHOD OF INTERMEDIATE COMPOUND FOR SYNTHESIZING MEDICAMENT LG Life Sciences Ltd (KR) 2013-07-10 EP disclosed
US-20130165659-A1 PRODUCTION METHOD OF INTERMEDIATE COMPOUND FOR SYNTHESIZING MEDICAMENT LG LIFE SCIENCES LTD. (KR) 2013-06-27 US disclosed
US-20130165659-A1 PRODUCTION METHOD OF INTERMEDIATE COMPOUND FOR SYNTHESIZING MEDICAMENT LG LIFE SCIENCES LTD. (KR) 2013-06-27 US disclosed
WO-2012030106-A2 PRODUCTION METHOD OF INTERMEDIATE COMPOUND FOR SYNTHESIZING MEDICAMENT LG LIFE SCIENCES LTD. (KR) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165659-A1 PRODUCTION METHOD OF INTERMEDIATE COMPOUND FOR SYNTHESIZING MEDICAMENT DPP4, DPP7, DPP8 CYP1A2 315/4885GAA 69/4885MGAM 204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.